Prognostic Value of BNP in MCS - a 25 Year Follow up Study

Rigshospitalet

Status: Enrolling

Conditions: Durable Mechanical Support Device; Left Ventricular Assist Device; Heart Failure; Prognosis

Treatments: Other: 2) Observation and collection and of blood sample; Other: Observation. No intervention per se.

Study type: Observational

Funder types: Other

Identifiers

NCT04377854

H-19055497

Details and patient eligibility

About

A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy.

Patients will be followed up for 25 years after inclusion.

Full description

All patients referred for advanced HF treatment at the Dept of Cardiology at Rigshospitalet.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark
• Age>18 years

Exclusion criteria

• No consent

Trial design

1,000 participants in 3 patient groups

MCS recipients

Description:

All recipients of durable MCS will be followed up on a yearly basis with collection of blood sample and clinical data for 25 years.

Treatment:

Other: 2) Observation and collection and of blood sample

Recipient of cardiac transplant

Description:

All recipients of cardiac transplantation(s) will be followed up on a yearly basis with collection of clinical data for 25 years.

Treatment:

Other: Observation. No intervention per se.

Watchful waiting at Rigshospitalet

Description:

Patients referred for evaluation for treatment with advanced treatment (LVAD/HTX) but -for whatever reason- these pts will be on watchful waiting at the Rigshospitalet.

Treatment:

Other: Observation. No intervention per se.